8-K: Terns Pharmaceuticals Holds 2024 Annual Meeting, Elects Directors and Ratifies Auditor

Terns Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing two Class III directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

Summary

• Terns Pharmaceuticals held its 2024 Annual Meeting of Stockholders on June 10, 2024.
• Stockholders voted on two proposals at the meeting.
• The first proposal was the election of two Class III directors, Jeffrey Kindler and Amy Burroughs, to hold office until the 2027 annual meeting.
• Jeffrey Kindler received 45,958,352 votes for, 6,735,358 votes withheld, and 5,131,121 broker non-votes.
• Amy Burroughs received 52,570,019 votes for, 123,691 votes withheld, and 5,131,121 broker non-votes.
• The second proposal was the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• This proposal received 57,570,954 votes for, 23,950 votes against, and 229,927 abstentions.
• There were 64,674,780 shares of common stock outstanding and entitled to vote as of the record date, April 18, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures, indicating a stable and routine operational environment. There are no indications of any issues or concerns.

Positives

• The election of directors and ratification of the auditor were successfully completed.
• Both proposals received a majority of votes in favor.

Industry Context

This is a routine annual meeting announcement, typical for publicly traded companies, ensuring corporate governance and compliance with SEC regulations.

Comparison to Industry Standards

• The election of directors and ratification of auditors are standard practices for publicly listed companies like Terns Pharmaceuticals.
• The voting results are typical for such meetings, with the majority of votes cast in favor of the proposals.
• Companies like BioMarin Pharmaceutical Inc. and Gilead Sciences Inc. also hold similar annual meetings to elect directors and ratify auditors.

Stakeholder Impact

• Shareholders have exercised their voting rights on key governance matters.
• The company has fulfilled its obligations to hold an annual meeting and report the results.

Key Dates

Keywords

Annual Meeting, Board of Directors, Director Election, Auditor Ratification, Ernst & Young, Shareholder Vote, Corporate Governance